Nonetheless, new biological strategies target epithelial‐derived alarmins such as IL‐33 (etokimab, itepekimab) and thymic stromal lymphopoietin (tezepelumab) in CRSwNP [46]. The gene discussed is TSLP; the disease is chronic rhinosinusitis with nasal polyps.